ReviewMedicinal research reviews2010
Looking toward basic science for potential drug discovery targets against community-associated MRSA.
Review in Medicinal research reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Current trends in pyrrole and porphyrin-derived nanoscale materials for biomedical applications.Nanomedicine (London, England) · 2020Review
- The anti-MRSA compound 3-O-alpha-L-(2″,3″-di-p-coumaroyl)rhamnoside (KCR) inhibits protein synthesis in Staphylococcus aureus.Journal of proteomics · 2020Article
- Does biofilm formation have different pathways inIranian journal of basic medical sciences · 2019Article
- Distinct virulent network between healthcare- and community-associatedClinical proteomics · 2018Article
- IsaB Inhibits Autophagic Flux to Promote Host Transmission of Methicillin-Resistant Staphylococcus aureus.The Journal of investigative dermatology · 2015Article
- HPLC Plasma Assay of a Novel Anti-MRSA Compound, Kaempferol-3-O-Alpha-L-(2",3"-di-p-coumaroyl)rhamnoside, from Sycamore Leaves.Natural product communications · 2015Article
- Neutrophil recruitment to lymph nodes limits local humoral response to Staphylococcus aureus.PLoS pathogens · 2015Article
- Article
- Phenotypic Variation Is Almost Entirely Independent of the Host-Pathogen Relationship in Clinical Isolates of S. aureus.PloS one · 2015Article
- The efficacy of the quorum sensing inhibitor FS8 and tigecycline in preventing prosthesis biofilm in an animal model of staphylococcal infection.International journal of molecular sciences · 2013Article
- Molecular modeling, dynamics studies and virtual screening of Fructose 1, 6 biphosphate aldolase-II in community acquired- methicillin resistant Staphylococcus aureus (CA-MRSA).Bioinformation · 2013Article
- Conserved small protein associates with the multidrug efflux pump AcrB and differentially affects antibiotic resistance.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Novel inhibitors of Staphylococcus aureus virulence gene expression and biofilm formation.PloS one · 2012Article
- Article
- Effect of low-concentration chlorine dioxide gas against bacteria and viruses on a glass surface in wet environments.Letters in applied microbiology · 2011Article
- Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?Expert review of anti-infective therapy · 2011Article
- Highly brominated antimicrobial metabolites from a marine Pseudoalteromonas sp.Journal of natural products · 2010Article
- The future of the β-lactams.Current opinion in microbiology · 2010Review
- Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine kinase and phosphatase.PloS one · 2010Article
- Penetration of the blood-brain barrier by Staphylococcus aureus: contribution of membrane-anchored lipoteichoic acid.Journal of molecular medicine (Berlin, Germany) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The difficulties to find a conventional vaccine against Staphylococcus aureus and the increasing resistance of S. aureus to many antibiotics demand the exploration of novel therapeutic options, such as by targeting virulence determinants and using specific antibodies in an antitoxin-like approach. Community-associated methicillin-resistant S. aureus (CA-MRSA) strains have recently emerged predominantly in the US, causing epidemic outbreaks of mostly skin and soft tissue infections, but also more dramatic and sometimes fatal diseases. MRSA is now the most frequent cause of death by a single infectious agent in the US. The fact that, at least in the US, CA-MRSA infections are almost entirely due to one sequence type, USA300, gives researchers a novel, unique chance to focus on one clone in their efforts to analyze pathogenesis in a clinically important S. aureus. While the molecular underpinnings of the exceptional virulence and transmissibility of USA300 are not yet well understood, recent findings indicate that increased expression of widespread virulence determinants and acquisition of mobile genetic elements have to be considered. Delineating the relative importance of virulence determinants in USA300 and other important clinical strains is a key endeavor needed to develop a potential antitoxin for CA-MRSA disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.